Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab with or without lenalidomide versus lenalidomide maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma
NL-OMON59720Phase 3Recruiting
- Sponsor
- European Myeloma Network B.V.
- Start
- Nov 2022
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Teclistamab + lenalidomide, Teclistamab monotherapy and Lenalidomide monotherapy (3 arms). Primary endpoints: Progression-free survival and 12-month MRD-negative complete response. Started Nov 2022; status: recruiting.
02
Drugs
teclistamablenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON59720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59720.